Table 2.
Percentage of Participants Determined to Be Highly Adherent to Their Assigned Treatment (as Measured by Pill Counts and Plasma Tenofovir Concentrationsa), by Study Month, Partners PrEP Study, 2008–2011
| Study Month |
No. of Persons |
% Adherent |
Concordance Between Measures, % |
|
|---|---|---|---|---|
| Pill Coverage 80%–107% |
Plasma Tenofovir Level >40 ng/mL |
|||
| 1 | 299 | 80 | 77 | 74 |
| 3 | 301 | 81 | 70 | 73 |
| 6 | 305 | 84 | 68 | 72 |
| 12 | 262 | 87 | 65 | 71 |
| 18 | 188 | 86 | 59 | 65 |
| 24 | 120 | 91 | 68 | 70 |
a Among participants with tenofovir concentrations measured in plasma. Participants were from 2 randomly selected cohorts from the study's active arms: 1) persons randomly selected from all participants at enrollment; 2) persons randomly selected from participants negative for herpes simplex virus type 2 at enrollment.